KP1019, a new redox‐active anticancer agent–Preclinical development and results of a clinical phase I study in tumor patients CG Hartinger, MA Jakupec, S Zorbas‐Seifried, M Groessl, A Egger, ... Chemistry & biodiversity 5 (10), 2140-2155, 2008 | 1041 | 2008 |
Recommendations for reporting ion mobility Mass Spectrometry measurements V Gabelica, AA Shvartsburg, C Afonso, P Barran, JLP Benesch, ... Mass spectrometry reviews 38 (3), 291-320, 2019 | 480 | 2019 |
Ligand substitutions between ruthenium–cymene compounds can control protein versus DNA targeting and anticancer activity Z Adhireksan, GE Davey, P Campomanes, M Groessl, CM Clavel, H Yu, ... Nature communications 5 (1), 3462, 2014 | 331 | 2014 |
Structure−Activity Relationships for NAMI-A-type Complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = Imidazole, Indazole, 1,2,4-Triazole, 4-Amino-1,2,4 … M Groessl, E Reisner, CG Hartinger, R Eichinger, O Semenova, ... Journal of medicinal chemistry 50 (9), 2185-2193, 2007 | 273 | 2007 |
High resolution ion mobility-mass spectrometry for separation and identification of isomeric lipids M Groessl, S Graf, R Knochenmuss Analyst 140 (20), 6904-6911, 2015 | 222 | 2015 |
Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity MG Mendoza-Ferri, CG Hartinger, MA Mendoza, M Groessl, AE Egger, ... Journal of medicinal chemistry 52 (4), 916-925, 2009 | 203 | 2009 |
A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core B Wu, MS Ong, M Groessl, Z Adhireksan, CG Hartinger, PJ Dyson, ... Chemistry–A European Journal 13 (17), 3562-3566, 2011 | 195 | 2011 |
Metal-based inhibition of poly (ADP-ribose) polymerase− the guardian angel of DNA F Mendes, M Groessl, AA Nazarov, YO Tsybin, G Sava, I Santos, ... Journal of medicinal chemistry 54 (7), 2196-2206, 2011 | 170 | 2011 |
Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs CG Hartinger, M Groessl, SM Meier, A Casini, PJ Dyson Chemical Society Reviews 42 (14), 6186-6199, 2013 | 165 | 2013 |
Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versuscisplatin M Groessl, O Zava, PJ Dyson Metallomics 3 (6), 591-599, 2011 | 160 | 2011 |
Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum (IV) complexes MR Reithofer, AK Bytzek, SM Valiahdi, CR Kowol, M Groessl, ... Journal of Inorganic Biochemistry 105 (1), 46-51, 2011 | 150 | 2011 |
Greener synthesis of new ammonium ionic liquids and their potential as extracting agents D Kogelnig, A Stojanovic, MS Galanski, M Groessl, F Jirsa, R Krachler, ... Tetrahedron Letters 49 (17), 2782-2785, 2008 | 148 | 2008 |
In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate‐based ligands I Berger, M Hanif, AA Nazarov, CG Hartinger, RO John, ML Kuznetsov, ... Chemistry–A European Journal 14 (29), 9046-9057, 2008 | 146 | 2008 |
Nanoscalic silver possesses broad-spectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazine O Brandt, M Mildner, AE Egger, M Groessl, U Rix, M Posch, BK Keppler, ... Nanomedicine: Nanotechnology, Biology and Medicine 8 (4), 478-488, 2012 | 135 | 2012 |
Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MS M Groessl, M Terenghi, A Casini, L Elviri, R Lobinski, PJ Dyson Journal of analytical atomic spectrometry 25 (3), 305-313, 2010 | 126 | 2010 |
Highly oxygenated multifunctional compounds in α-pinene secondary organic aerosol X Zhang, AT Lambe, MA Upshur, WA Brooks, A Gray Bé, RJ Thomson, ... Environmental science & technology 51 (11), 5932-5940, 2017 | 125 | 2017 |
Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry M Groessl, YO Tsybin, CG Hartinger, BK Keppler, PJ Dyson JBIC Journal of Biological Inorganic Chemistry 15, 677-688, 2010 | 125 | 2010 |
CZE–ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP M Groessl, CG Hartinger, PJ Dyson, BK Keppler Journal of inorganic biochemistry 102 (5-6), 1060-1065, 2008 | 110 | 2008 |
Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules M Hanif, AA Nazarov, A Legin, M Groessl, VB Arion, MA Jakupec, ... Chemical Communications 48 (10), 1475-1477, 2012 | 109 | 2012 |
Ion mobility–mass spectrometry of supramolecular complexes and assemblies E Kalenius, M Groessl, K Rissanen Nature Reviews Chemistry 3 (1), 4-14, 2019 | 108 | 2019 |